loader from loading.io

JDRF & Beyond Type 1 CEOs Explain Their New Alliance (Bonus Episode)

Diabetes Connections | Type 1 Diabetes

Release Date: 10/16/2019

GLP-1s for Type 1 Diabetes: Are We  There Yet? With Dr. Cecilia Low Wang show art GLP-1s for Type 1 Diabetes: Are We There Yet? With Dr. Cecilia Low Wang

Diabetes Connections | Type 1 Diabetes

One of the sure-thing top stories of 2026 will be GLP1s, but will we see more studies and even approval for treating type 1 with these medications? We're talking about Ozempic, Mounjaro and the next versions like Retatrutide - that are just around the corner. I’m talking to  Dr. Cecelia Lo Wong, a diabetologist at the University of Colorado whose been on the front lines of this conversation for years,  including serving on FDA advisory committees. This is a wide ranging interview - we also talk about the growing needs of older adults with type 1 diabetes, how kidney and...

info_outline
In the News PLUS our 2026 Predictions show art In the News PLUS our 2026 Predictions

Diabetes Connections | Type 1 Diabetes

It's In the News.. a look at the top headlines and stories in the diabetes community. This week we're also making predictions for diabetes news in 2026! This week's top stories: statins and type 2, big results from Lilly's newest weight loss drug, MiniMed IPO, Tandem app update, and more! Predicitons include thouhts around: continuous ketone monitoring, noninvasive gucose moniotring, inhalable insulin for kids, GLP1 backlash, A1 slop in diabetes mom groups and more! Announcing Community Commericals! Learn how to  Learn more about  Please visit our Sponsors & Partners -...

info_outline
Looking back on 2025: Hype, hope and what really matters, with Neil Greathouse show art Looking back on 2025: Hype, hope and what really matters, with Neil Greathouse

Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections, a conversation about what really matters in diabetes. We’re talking about the top stories of 2025, the hype that didn’t happen, some trends for 2026, what community can accomplish, and what LeBron James has to do with all of this. We also get personal – because I’m being interviewed by the wonderful Neil Greathouse, host of Your Best T1D life, and so much more. This episode contains a replay of This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community...

info_outline
Do We Need an At-Home A1C Test in the  Age of CGM? Orange Biomed Says Yes show art Do We Need an At-Home A1C Test in the Age of CGM? Orange Biomed Says Yes

Diabetes Connections | Type 1 Diabetes

Making the case for a better at home A1C test. Orange Biomed is developing a compact, one-drop, at-home A1C testing device they say could make frequent A1C checks easier and more accessible than ever. They’re passionate about closing the gap for people who struggle to get to clinics regularly… and the research they share is compelling: four A1C tests a year can lead to a nearly 4% reduction in A1C levels. We’ll talk about why more frequent A1C monitoring matters—even in the era of continuous glucose monitoring—how their new device works, and what early clinical trial results look...

info_outline
She Turned Her Glucose Data Into Art. Could it Change How People See Diabetes? show art She Turned Her Glucose Data Into Art. Could it Change How People See Diabetes?

Diabetes Connections | Type 1 Diabetes

What if your glucose graph became a tangible piece of art? Something you could pring out and put on your water bottle or the back of your laptop. I’ve seen this in person and it makes a big impact on people. This week I’m talking to Krista Shenaman about making this type of art, her journey with type 2 – and it’s been a journey, she took a “record breaking” 28 day walk after her diagnosis.. – why she thinks its helpful to look at data in a new way and more.    Full disclosure: We recorded this interview way back in 2024! Technical issues and thought it was lost,...

info_outline
Dexcom’s 15-Day G7 Is Here: What’s Changing, What’s Next, and What You Need to Know show art Dexcom’s 15-Day G7 Is Here: What’s Changing, What’s Next, and What You Need to Know

Diabetes Connections | Type 1 Diabetes

It’s been a big month for announcements from Dexcom! What does that mean for you?  From the commercial launch of the 15 day sensor and a smart basal feature to the announced phase out of the G6 and more, I’m talking with Jessica Castle, vice president of Global Medical Affairs at Dexcom. We’re covering all of this news and she’s answering your questions. More about More about This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to  Learn more about ...

info_outline
Inside Capitol Hill’s Fight for Diabetes Care: What These Advocates Need You to Know show art Inside Capitol Hill’s Fight for Diabetes Care: What These Advocates Need You to Know

Diabetes Connections | Type 1 Diabetes

We're looking at some major policy issues happening in Washington, and what you can really do to effect change. George Huntley is the CEO of . We’ve got a lot to cover: Medicare changes like competitive bidding that could dramatically limit access to CGMs and insulin pumps for seniors, the changing landscape around GLP 1 meds, and we talk about patient advocacy wins. I know some of you are cynical, but it can work. If you’ve ever thought your voice doesn’t matter, this conversation may change your mind. This podcast is not intended as medical advice. If you have those kinds of questions,...

info_outline
In the News... Libre Freestyle recall, Dexcom 15 day launch, Omnipod & Tandem updates, Medicare price adjustments and more! show art In the News... Libre Freestyle recall, Dexcom 15 day launch, Omnipod & Tandem updates, Medicare price adjustments and more!

Diabetes Connections | Type 1 Diabetes

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out  Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Learn more about   from extreme temperatures The best way to keep up with Stacey and the show is by...

info_outline
Preventing Type 1 Diabetes? Dr. Michael Haller on ATG Research (Plus, Afrezza for Kids) show art Preventing Type 1 Diabetes? Dr. Michael Haller on ATG Research (Plus, Afrezza for Kids)

Diabetes Connections | Type 1 Diabetes

We've got a research update on two of the topics you’ve told me you want to hear more about. First, research into Preventing type 1 – with a therapy that hasn’t been in the headlines.. and second, inhaled insulin for kids. We’re talking to , a peds endo who is at the forefront of these studies. We’ll be talking about something called ATG – which looks really good in very low dose trials – and about the latest studies around inhaled insulin for kids – which is in front of the FDA right now. This podcast is not intended as medical advice. If you have those kinds of questions,...

info_outline
Rethinking Type 1 Screening with Adam Schefter & Dr. Shara Bialo show art Rethinking Type 1 Screening with Adam Schefter & Dr. Shara Bialo

Diabetes Connections | Type 1 Diabetes

With lots of family time coming up this week for many of us, it’s a great time to talk about screening for type 1. While this might seem to be a real downer of a Thanksgiving conversation, screening is now considered standard of care for people with a family history of T1D. My guests want to get the word out about that – and they’ve both walked the walk. Adam Schefter is ESPN Senior NFL Insider – his wife lives with type 1.. and Dr. Shara Bialo is a pediatric endo who lives with type 1. This podcast is not intended as medical advice. If you have those kinds of questions, please contact...

info_outline
 
More Episodes

What happens when two huge diabetes organizations decide to work together? We're all about to find out. Stacey talks to the CEOs of JDRF & Beyond Type 1 about their newly announced "alliance."

Buy Stacey's Book - "The World's Worst Diabetes Mom"

JDRF's Aaron Kowalski and Beyond Type 1's Thom Scher join Stacey for a talk about why these groups came together and what that means for the diabetes community.

Join the Diabetes Connections Facebook Group!

More info about the announcement here

Sign up for our newsletter here

-----

Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
-----

Get the App and listen to Diabetes Connections wherever you go!

Click here for iPhone      Click here for Android

-----------

Partial transcript of the episode:

Stacey: Can you talk a little bit about the story behind [the alliance]?

Thom: I think that both JDRF and Beyond Type 1 are strong and important in this space. Aaron and I sat down and it was very clear that there were areas of overlap in the middle of the Venn diagram of sorts where we realized that working together, and this sounds a little cheesy, but where it really would be 1+1=3… And the minute we identified that list of things, it just became very clear that we were stronger together on a handful of these initiatives.

 

I also think, and this certainly isn’t something that our organizations were trying to do, but inevitably I think that we, people in the community sometimes feel like they had to pick, and that’s silly. We’re all in this together. We’re all fighting to improve the lives of people impacted by diabetes. I think JDRF and Beyond Type 1 saw that and saw that we were able to really work together and build something robust and official that allows both organizations to now go out and do these things together.

 

Is this a merger? You’ve talked about eliminating some redundancies – can you speak to that?

Aaron: We’re going to stay independent organizations, but it is reducing redundancies and building on what one another do well. From my perspective, when I took on the CEO role of JDRF, I talked to the board about a couple of key things. One is: what is JDRF really good at? I think we’re really good at funding research. We fund more research than anybody but the U.S. government. We’ve been successful at advocacy, and our mission has really been improving lives and curing Type 1 diabetes. Beyond Type 1 has been an incredible force in uniting our community… Beyond Type 1 has engaged with the adult community certainly better than we have.

 

What is the latest from JDRF in terms of pushing for insulin affordability?

Aaron: This is one of our top advocacy issues that we’re dealing with now. I’ve said this multiple times, I’ve testified on the Hill three times on this topic. No one should suffer or die for lack of insulin. And what we have in the United States is a shameful situation. JDRF is fully committed that nobody should have to choose between rent or a car payment or insulin. So we’ve been working on a number of fronts with the payer community, with Congress, looking at people who are under or uninsured, and looking at every remedy possible. I can tell you that working with Beyond Type 1, I think we’re going to be a be able to amplify this message. To me, it’s of course about amplifying the message, but it’s about driving towards solutions.

 

Thom: I’ll build off of that. I think we certainly are looking forward to working with JDRF to be more impactful in this arena of bringing more patient voices into the conversation, certainly at a federal level. I think our perspective at Beyond Type 1 on this is that we need to look for a pragmatic solution. And on top of those pragmatic solutions, we need to be ensuring that we are providing resources every day to people who are in need of insulin. And so some of those pragmatics take the form of actual policy matters be it first dollar coverage or Kevin’s Law. Some of the resource components have to do with ensuring that, for example, people who are uninsured know what assistance programs are available to them, they know how to get to them, they know that with them they will have coverage. There are robust programs in particular for that population. It’s that the barriers to entry are too high. So we’re really committed to building out our advocacy forum of Beyond Type 1 over the course of the next year.

 

This alliance was a big part of that because we now get to work with JDRF, a leading organization on that front, leveraging their expertise and bringing it into our community, and that’s a stepping stone for us to take more meaningful steps.

 

Did you know each other before you started talking about this?

Thom: I consider Aaron a friend, and a colleague, and I love working with him. I don’t think Aaron and I knew each other all that well when we each respectively took over as CEOs, though I certainly knew of Aaron and respected Aaron. I think Aaron and I over series of conversations in person and by phone have definitely gotten closer. I feel really lucky to call Aaron a friend now. I think that certainly informed some of the creation of the alliance. It was Aaron and I being able to really sit down and talk at a high level, everything on the table, how can we work together? That came from a place, at least on my end of [inaudible 00:11:59] Aaron’s vision and a belief that him and I were going to be able to work together and so would our teams. So no, we were not necessarily friends before this, but I certainly consider us friends today.

 

Aaron: Thom came down to the JDRF office in New York City and we sat down and talked, and really, it was quite clear that we were so aligned in where we were trying to take both of these organizations. So we hadn’t met before that and here we are. We took this selfie, and now today in October 2019 I think Thom is a great diabetes friend, and friend just the overall. I always love seeing, we love seeing one another. I mean it’s funny. Diabetes is one of those places I always call it the club that we want no more members of, but you find amazing people who are in this club unfortunately. Thom is just one of those amazing people whose leaned in, he’s just such a joy to work with, and we are going to do amazing things together. I’m just so fortunate that now that we have this bond.